This study is exploring the use of lasmiditan for treating migraines in children aged 6 to 17. Migraines are severe headaches that can cause pain, nausea, and sensitivity to light. Lasmiditan is a medication that could help with these symptoms. The study lasts for 12 months, during which children may have up to 7 visits to the clinic. To join, participants need to have finished a previous related study and weigh at least 15 kilograms (about 33 pounds).

However, children who are pregnant, nursing, or have serious health issues cannot join. Also, those at risk of harming themselves are not eligible. This study is open-label, meaning everyone will know they are receiving lasmiditan, not a placebo (a sugar pill). It's essential to understand the potential risks and benefits before joining.

• The study lasts about 12 months with up to 7 visits.
• Participants must have completed a previous study.
• Children must weigh at least 15 kilograms.